In this study, we evaluated the effect of lower urinary tract dysfunction and its neuromodulative therapy on sexual functioning. We studied 121 patients with an overactive bladder (OAB) (N ¼ 83), chronic pelvic pain (N ¼ 23) and nonobstructive retention (N ¼ 15), which were treated with neuromodulation (i.e. percutaneous tibial nerve stimulation, PTNS). To obtain information on their sexual function, a self-administered standardized questionnaire was filled out before therapy as well as after 12 weeks of treatment. Before therapy, different aspects of sexual life were considered not normal in 25.3-45.6% of the cases. This improved significantly after treatment. Patients most likely to benefit were women, patients with an OAB and subjective responders. The aspects of sexual life which mostly improved were overall satisfaction, libido and the frequency of sexual activities. Sexual dysfunction is observed in a lot of patients with lower urinary tract disorders and may improve on successful therapy for the latter.
Introduction
Nonneurogenic lower urinary tract dysfunction (LUTD) is a common urological problem that strongly affects the quality of life. Although, in general quality of life issues gain more attention in studies performed, effects of disorders and therapies on sexual life are only rarely investigated. This is particularly true for patients with an overactive bladder (OAB), chronic pelvic pain (CPP) and nonobstructive urinary retention. Most publications that do consider sexual impairment in incontinence patients regard female patients only and describe groups suffering from stress or mixed incontinence. 1, 2 For our study, we hypothesized that a considerable amount of patients with LUTD has impaired sexual life and that patients with impaired sexual life benefiting from therapy for their urological complaints also improve with regard to sexual functioning. Therefore, patients with OAB, CPP and nonobstructive urinary retention undergoing percutaneous tibial nerve stimulation (PTNS) were to be evaluated with self-administered standardized questionnaires regarding sexual functioning before and after finishing therapy.
Patients and methods
Between November 1999 and August 2001, 121 patients (45 male, 76 female) with CPP, nonobstructive urinary retention or OAB were enrolled in a prospective clinical multicenter trial to evaluate the effect of PTNS on these lower urinary tract disorders. The trial got approval by the Institutional Review Boards. Reports on clinical outcome were published recently. [3] [4] [5] [6] As part of this study sexual functioning has been evaluated as well as possible effects of PTNS on sexual impairment.
Patients
A total of 45 male and 76 female patients, mean age 53.6 years (range 21-82 years) have been treated for LUTD. Mean age of male (54.4 years, range 21-76 years) and female patients (53.1 years, range 23-82 years) did not differ significantly. Fifteen patients (six males, nine females) were treated for nonobstructive retention, 23 patients (17 males, six females) for CPP and 83 patients (22 males, 61 females) for OAB. Median duration of lower urinary tract complaints was 4 years (range 1-56 years). No statistical significant differences in median duration of symptoms were seen between sexes or subgroups. Physical examination did not show overt (neurourological) abnormalities in any of these patients (see Table 1 ).
Method of treatment
Percutaneous tibial nerve stimulation was applied according to Stoller 7 and Govier et al. 8 A percutaneous inserted 34 gauge needle approximately 3-4 cm cephalad to the medial malleolus and a stick-on electrode placed on the same leg near the arch of the foot have been used for electrical stimulation with an adjustable pulse intensity (0-10 mA), a fixed pulse width of 200 ms and a frequency of 20 Hz. The stimulator contained a battery of 9 V (Urgent PC s , CystoMedix, Anoka, MN, USA). In case of a good motor response, generally accompanied by a specific sensory response, stimulation current was set at a well-tolerable level. Patients underwent 12 weekly outpatient treatment sessions of half an hour each without in-between stimulations.
In case of a good response on their lower urinary tract symptoms patients were offered chronic treatment.
Evaluation of results
After informed consent, all patients had to fill out micturition or pain diaries as well as general (SF-36 9 ) and disease-specific quality of life questionnaires (McGill Pain Questionnaire Dutch Language Version 10 and I-Qol 11 ) at study entry and at completion of treatment at 12 weeks. Subjective response was defined as the request of patients to continue chronic treatment to keep the obtained response, objective success as a decrease in symptoms (i.e. number of voids/24 h, number of incontinence episodes/24 h, number of catherizations/ 24 h or score on the Visual Analogue Scale for pain) of over 50%.
The sexual functioning before PTNS as well as after 12 weeks of treatment was studied by means of a standardized questionnaire to be filled out by the patients. This 'Nine questions regarding Sexual Functioning, Dutch language version' (NSF-9) was constructed by Vroege, 12 has been described in English literature by Francken et al. 13 and is available in equally constructed versions for men and women. In the NSF-9 sex is considered as 'coitus, but also other forms of contact that you find sexually arousing' (see also Appendix A). Table 1 ).
At baseline, 88.4% filled out the NSF-9, after 12 weeks of PTNS this percentage decreased to 86%.
To the question, before PTNS, to what extent patients were satisfied with their current sex life, 40 patients answered 'dissatisfied' or 'very dissatisfied'. In this group satisfaction over all improved significantly (Po0.005). Improvement was mainly seen in female patients (N ¼ 22, Po0.005), OAB patients (N ¼ 22, Po0.05) and subjective responders (N ¼ 16, Po0.05) (see Table 2 ).
Patients answering (before PTNS) 'neutral' to 'very satisfied' with their sex life remained as satisfied after the treatment (P ¼ 0.2).
The improved satisfaction with their current sex life also resulted in a change in frequency of 'feeling like having sexual contact' as well as 'actually having sexual contact' (Po0.005 in 46 and 47 patients, respectively, formerly answering these questions with 'not at all' and 'once in the past month'). As in the question on satisfaction, changes were predominantly observed in female patients (N ¼ 30 and N ¼ 29, Po0.005) . The same applies to OAB patients (N ¼ 34, both) and subjective responders (N ¼ 20 and N ¼ 22): all Po0.05 (see Table 3 ). Patients that 'felt like having sexual contact' at least several times a month or 'actually had sexual contact' at least several times a month before PTNS, remained doing so afterwards (P ¼ 0.3 and 0.8).
The aforementioned improvements could not be related to changes in pain in the genital regions during sexual contact or disturbances in vaginal lubrication or erectile functioning. However, together with changes in frequency of wanting or having sex and sexual satisfaction, significant improvements were seen in OAB patients never having reached an orgasm during sexual activity in the past month, as well as in female patients reaching orgasms too fast or too slowly. Seventeen out of 29 OAB patients that, before PTNS, did not reach orgasms although being sexually active, did so afterwards (Po0.05), while 11 out of 26 female patients reaching orgasms too fast and 21 out of 32 female patients reaching orgasms too slowly significantly improved (both: Po0.05).
Discussion
In a recent review by Shaw on the prevalence of sexual impairment in female patients with urinary incontinence 1 figures widely varied between 0.6 and 64%. Most studies dealt with female patients with stress incontinence only, mixed groups or patients with 'any involuntary urine loss'. In the few cases clear detrusor instability has been regarded, impair- Sexual functioning in patients with lower urinary tract dysfunction MR van Balken et al ment mostly was found in 10-35% of patients, depending on the way impairment was defined. More recent reports reconfirm the negative way in which OAB may affect sexual function in female patients. 2, 14 For other forms of LUTD, especially nonurinary retention, as well as for male patients with urinary symptoms, data on sexual impairment are very scarce. In a Danish survey in over 7000 people Hansen showed recently that lower urinary tract symptoms are an independent risk factor for sexual dysfunction in both women and men. 15 In our study, questions of the NSF-9, a standardized Dutch-language questionnaire dealing with different aspects of sexual functioning, revealed abnormal sexual functioning in 25.3-45.6% of all cases. In patients with OAB, sexual dysfunction has been observed in about a quarter to one-third of cases being in accordance to the above-mentioned literature. It should be noted that sexual dysfunction in our study might be underreported, as about 12% of the treated patients did not fill out the questionnaires. However, due to widely differing definitions of impairment of sexual function, urinary incontinence as well as sexual activity in different reports, useful comparisons cannot be made. This is further hampered by the fact that in the Netherlands, validated questionnaires on sexual functioning hardly exist, let alone questionnaires that can be used for female as well as male patients. The NSF-9 is equally constructed for male and female patients. It is short, enhancing compliance, and especially suitable for the Dutch language, but we are aware of the fact that it does not contribute to uniformity in international research.
Our intent was not only to establish some indication on the prevalence of sexual impairment in patients with LUTD, but also to find out whether improvement of the latter improved sexual functioning as well. One of the difficulties regarding this subject is the possibility that complaints of urinary symptoms may be the result of sexual dysfunction rather than the cause. In that case treating the sexual problem itself, instead of the LUTD, might be of more importance. 1 In this study, treatment of the LUTD has been performed by means of PTNS. Our earlier studies revealed PTNS' success rates on lower urinary tract symptoms up to 70%, 3-5 much higher than was observed here. It should be mentioned that those studies were performed in only a few high volume centers. The data presented in this paper are pooled data from our own center with those from several low volume hospitals in the Netherlands, that all used the same protocol. Results in these added centers were worse, although not statistically significant. Furthermore, a discrepancy was observed between the number of subjective and objective responders. One should bear in mind that most patients underwent many therapies before using PTNS as a final option. Small changes, not enough for objective success, may therefore have been consi- Sexual functioning in patients with lower urinary tract dysfunction MR van Balken et al dered enough to pursue chronic treatment. Besides, especially in OAB-patients, not only the number of voids/24 h and the number of incontinence episodes/24 h are of importance. The urge severity and the time patients can postpone micturition also play a role. Patients experiencing the most improvement of these items, more than of objective criteria, may be subjectively successful, objectively they are not. Although compliance to the NSF-9 was rather high, the above-mentioned low objective response rate to PTNS and the also rather small number of patients in each investigated subgroups, like, among others gender and indication for PTNS, made it difficult to obtain fair statistics on separate NSF-9 items per subgroup. It was therefore chosen to perform the other way around: separate NSF-9 items have been investigated and its changes correlated to the subgroups.
However, bearing these shortcomings in mind, we still feel our study proved that in particular sexually impaired female patients suffering from OAB, subjectively responding to PTNS, also benefited from LUTD treatment with regard to their sexual functioning. They were more satisfied and were more frequently sexually active than before PTNS. A possible explanation might be the positive effects on the fear for involuntary urine loss or actual incontinence during sexual activity. Female patients with involuntary urine loss frequently feel dirty, fear smells and therefore have a low self-esteem, emotions likely to disappear with resolving urinary symptoms. Male patients, in whom sexual functioning is highly related to the way erectile functioning is experienced and not so much to urinary symptoms during sexual activity, may therefore not have the same positive outcome on successful LUTD therapy.
In conclusion, sexual dysfunction was observed in about one-third of patients with lower urinary tract disorders and improved significantly on successful therapy for the latter. Female patients, patients with OAB and subjective responders were most likely to improve.
